Analyst Ratings For NASDAQ:IONS – Ionis Pharmaceuticals (NASDAQ:IONS)
Today, Stifel Nicolaus lowered its price target on NASDAQ:IONS – Ionis Pharmaceuticals (NASDAQ:IONS) to per share.
Some recent analyst ratings include
- 2/20/2018-Sanford C. Bernstein Reiterated Rating of Market Perform.
- 10/17/2017-Needham & Company LLC Reiterated Rating of Buy.
- 10/6/2017-Goldman Sachs Reiterated Rating of Sell ➝ Sell.
Recent Insider Trading Activity For NASDAQ:IONS – Ionis Pharmaceuticals (NASDAQ:IONS)
NASDAQ:IONS – Ionis Pharmaceuticals (NASDAQ:IONS) has insider ownership of 2.44% and institutional ownership of 91.02%.
- On 4/17/2018 Stanley T Crooke, Chairman, sold 13,962 with an average share price of $44.40 per share and the total transaction amounting to $619,912.80.
- On 3/29/2018 Joseph Klein III, Director, sold 2,000 with an average share price of $46.15 per share and the total transaction amounting to $92,300.00.
- On 3/15/2018 Joseph Klein III, Director, sold 2,000 with an average share price of $51.13 per share and the total transaction amounting to $102,260.00.
- On 3/12/2018 Patrick R O’neil, SVP, sold 1,000 with an average share price of $55.00 per share and the total transaction amounting to $55,000.00.
- On 2/28/2018 Joseph Klein III, Director, sold 3,000 with an average share price of $51.91 per share and the total transaction amounting to $155,730.00.
- On 2/15/2018 Joseph Klein III, Director, sold 3,000 with an average share price of $48.99 per share and the total transaction amounting to $146,970.00.
- On 2/1/2018 C Frank Bennett, SVP, sold 12,500 with an average share price of $52.50 per share and the total transaction amounting to $656,250.00.
Recent Trading Activity for NASDAQ:IONS – Ionis Pharmaceuticals (NASDAQ:IONS)
Shares of NASDAQ:IONS – Ionis Pharmaceuticals closed the previous trading session at 44.31 up +0.30 0.68% with shares trading hands.